This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/russia/536259-sputnik-vaccine-trials-elderly/

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Russia’s Sputnik V vaccine successfully completes third & final phase clinical trials among elderly, Health Minister reveals Russia’s Sputnik V vaccine successfully completes third & final phase clinical trials among elderly, Health Minister reveals
(21 days later)
The third phase clinical trials of the Sputnik V vaccine against Covid-19 among those aged over 60 have been successfully completed, with the jab proving its safety and effectiveness, Russia’s Health Minister revealed on Thursday.The third phase clinical trials of the Sputnik V vaccine against Covid-19 among those aged over 60 have been successfully completed, with the jab proving its safety and effectiveness, Russia’s Health Minister revealed on Thursday.
More than 23,000 elderly patients took part in the final stage of the survey, Mikhail Murashko said during a meeting of the government’s coordination council on tackling Covid-19 on Thursday.More than 23,000 elderly patients took part in the final stage of the survey, Mikhail Murashko said during a meeting of the government’s coordination council on tackling Covid-19 on Thursday.
The vaccine has shown a “high safety and effectiveness profile” in the most vulnerable age group, the minister insisted, without revealing any exact figures. The final report on the results of the trials is currently being prepared, he added.The vaccine has shown a “high safety and effectiveness profile” in the most vulnerable age group, the minister insisted, without revealing any exact figures. The final report on the results of the trials is currently being prepared, he added.
The Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology, which developed Sputnik V, will prepare new medical indications for the use of the jab based on the results of the latest tests, Murashko said.The Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology, which developed Sputnik V, will prepare new medical indications for the use of the jab based on the results of the latest tests, Murashko said.
Sputnik V became the world’s first registered vaccine against the coronavirus after being approved by Russian authorities last August.Sputnik V became the world’s first registered vaccine against the coronavirus after being approved by Russian authorities last August.
The jab has shown a high efficacy of 97.6% among those who received both required shots, while also boasting a lack of any significant known side effects. The jab has shown a high efficacy of 97.6% among those who received both required shots, while also boasting a lack of any significant known side effects. 
The Russian vaccine has garnered praise in the international scientific community, including from the prestigious medical magazine The Lancet, and has already been approved in 70 countries. The Russian vaccine has garnered praise in the international scientific community, including from the prestigious medical magazine The Lancet, and has already been approved in 70 countries. 
However, Sputnik V is still lacking authorization from the EU's regulator, the European Medicines Agency (EMA), and the World Health Organization (WHO), with Moscow officials suggesting that the protracted registration process could be motivated by political reasons.However, Sputnik V is still lacking authorization from the EU's regulator, the European Medicines Agency (EMA), and the World Health Organization (WHO), with Moscow officials suggesting that the protracted registration process could be motivated by political reasons.
Like this story? Share it with a friend!Like this story? Share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.